Evidence map›Paper›PMID 36198882›Full record

ArticleMolecular neurobiology2022

Nuclear Inhibitor of Protein Phosphatase 1 (NIPP1) Regulates CNS Tau Phosphorylation and Myelination During Development.

Cody McKee, Peter Shrager, Arindam Gosh Mazumder, Archan Ganguly, Abigail Mayer, Karl Foley, Nancy Ward, Margaret Youngman, Hailong Hou, Houhui Xia

Abstract read
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Sut-6/NIPP1 modulates tau toxicity.Human molecular genetics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cody McKeeNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Peter ShragerNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Arindam Gosh MazumderDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Archan GangulyDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Abigail MayerNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Karl FoleyNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Nancy WardDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Margaret YoungmanNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Hailong HouDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA. hlhou@live.com.
Houhui XiaNeuroscience Graduate Program, Department of Neuroscience, University of Rochester Medical Center, Rochester, NY, 14642, USA. houhui_xia@urmc.rochester.edu.ORCID http://orcid.org/0000-0001-6806-7736

Funding

Inhibitor-2 is a positive regulator for PP1's synaptic and cognitive functionsR01MH109719 · NIMH · UNIVERSITY OF ROCHESTER · PI XIA, HOUHUI · 2016 to 2020
$1.9M
Protein phosphatase 1 isoforms and human de novo mutations in synaptic plasticityF30MH122046 · NIMH · UNIVERSITY OF ROCHESTER · PI FOLEY, KARL FRANCIS WILSON · 2020 to 2023
$205k
NIMH NIH HHS F30 MH122046NIMH NIH HHS R01 MH109719USNIH NIH F30 MH122046USNIH NIH R01 MH109719USNSF NSF IOS-1457336
6 · The paper itself

Abstract

Nuclear inhibitor of protein phosphatase 1 (NIPP1) is a known regulator of gene expression and plays roles in many physiological or pathological processes such as stem cell proliferation and skin inflammation. While NIPP1 has many regulatory roles in proliferating cells, its function in the central nervous system (CNS) has not been directly investigated. In the present study, we examined NIPP1 CNS function using a conditional knockout (cKO) mouse model in which the Nipp1 gene is excised from neural precursor cells. These mice exhibited severe developmental impairments that led to premature lethality. To delineate the neurological changes occurring in these animals, we first assessed microtubule-associated protein tau, a known target of NIPP1 activity. We found that phosphorylation of tau is significantly enhanced in NIPP1 cKO mice. Consistent with this, we found altered AKT and PP1 activity in NIPP1 cKO mice, suggesting that increased tau phosphorylation likely results from a shift in kinase/phosphatase activity. Secondly, we observed tremors in the NIPP1 cKO mice which prompted us to explore the integrity of the myelin sheath, an integral structure for CNS function. We demonstrated that in NIPP1 cKO mice, there is a significant decrease in MBP protein expression in the cortex, along with deficits in both the conduction of compound action potentials (CAP) and the percentage of myelinated axons in the optic nerve. Our study suggests that NIPP1 in neural precursor cells regulates phosphorylation of tau and CNS myelination and may represent a novel therapeutic target for neurodegenerative diseases.

Indexed as

Intracellular Signaling Peptides and ProteinsNeural Stem CellsAnimalsCentral Nervous SystemMiceMyelin SheathPhosphorylationProtein Phosphatase 1Intracellular Signaling Peptides and ProteinsProtein Phosphatase 1Compound action potential (CAP)Knockout mouseMyelinationNuclear inhibitor of protein phosphatase 1 (NIPP1)PhosphorylationTau

Identifiers

PMID36198882
PMCPMC9724999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.